Distilling Phase 3 Commencing of BMS’ LPA1 Antagonist for IPF & PPF

Time: 9:00 am
day: Day One


• Investigating the current clinical development and progress of BMS’ lysophosphatidic acid receptor 1 (LPA1) antagonist

• Exploring phase 2 readouts implications on phase 3 study design and exploring the process of enrolling a large-scale phase 3 study